Anti-KDR Antibody (MOM-18079)
|Recombinant Anti-Human KDR Antibody
- Product Overview
- Recombinant Human Antibody is bind to Human VEGF Receptor 2, expressed in Chinese Hamster Ovary cells(CHO)
- Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, WB and most other immunological methods.
- Specific Activity
- Tested positive against native antigen.
- Protein Construction
- Immunoglobulin G1, anti-(human vascular endothelial growth factor receptor type VEGFR-2 extracellular domain) (human monoclonal IMC-1121B γ-chain), disulfide with human monoclonal IMC-1121B kappa-chain, dimer
- >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
- Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.
- Antigen Description
- Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi"s sarcoma lesions.
- ATP binding; Hsp90 protein binding; growth factor binding; integrin binding; nucleotide binding; protein binding; protein tyrosine kinase activity; receptor activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; vascular endothelial growth factor-activated receptor activity;
- KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); vascular endothelial growth factor receptor 2; CD309; FLK1; VEGFR; VEGFR2; soluble VEGFR2; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.